MK-677 (Ibutamoren) Research & Studies
We track 20 published, PubMed-indexed studies for MK-677 (Ibutamoren), spanning 1996 to 2025. The research below includes 4 reviews, 16 clinical trials.
These summaries are for educational purposes. Research findings, particularly from preclinical studies, may not translate to human outcomes. Always consult a qualified healthcare provider before making decisions based on this information.
4
Reviews
16
Clinical Trials
New directions in growth hormone treatment in children.
ReviewStawerska R|Pediatr Endocrinol Diabetes Metab|2025
Treatment of Pediatric Growth Hormone Deficiency With Oral Secretagogues Revisited.
ReviewYau M, Rapaport R|J Endocr Soc|2021
Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.
ReviewSinha DK, Balasubramanian A, et al.|Transl Androl Urol|2020
Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study.
Clinical TrialCampbell GA, Patrie JT, et al.|Nephrol Dial Transplant|2018
The Safety and Efficacy of Growth Hormone Secretagogues.
ReviewSigalos JT, Pastuszak AW|Sex Med Rev|2018
MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.
Clinical TrialAdunsky A, Chandler J, et al.|Arch Gerontol Geriatr|2011
Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.
Clinical TrialSevigny JJ, Ryan JM, et al.|Neurology|2008
The effect of treatment with the oral growth hormone (GH) secretagogue MK-677 on GH isoforms.
Clinical TrialSvensson J, Boguszewski CL, et al.|Growth Horm IGF Res|2003
Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
Clinical TrialCodner E, Cassorla F, et al.|Clin Pharmacol Ther|2001
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Clinical TrialMurphy MG, Weiss S, et al.|J Clin Endocrinol Metab|2001
Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
Clinical TrialMurphy MG, Bach MA, et al.|J Bone Miner Res|1999
Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677.
Clinical TrialSvensson J, Carlsson B, et al.|Clin Endocrinol (Oxf)|1999
Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a).
Clinical TrialSvensson J, Jansson JO, et al.|J Clin Endocrinol Metab|1999
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
Clinical TrialMurphy MG, Plunkett LM, et al.|J Clin Endocrinol Metab|1998
Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.
Clinical TrialSvensson J, Ohlsson C, et al.|J Bone Miner Res|1998
Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
Clinical TrialSvensson J, Lönn L, et al.|J Clin Endocrinol Metab|1998
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man.
Clinical TrialCopinschi G, Leproult R, et al.|Neuroendocrinology|1997
Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
Clinical TrialChapman IM, Pescovitz OH, et al.|J Clin Endocrinol Metab|1997
Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.
Clinical TrialChapman IM, Bach MA, et al.|J Clin Endocrinol Metab|1996
Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.
Clinical TrialCopinschi G, Van Onderbergen A, et al.|J Clin Endocrinol Metab|1996